Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20482071 | 0.87 | LARS1 (0.43) | LARS1 | |
| SCHEMBL23022874 | 0.82 | CXCR4 (0.44) | LARS1HTR1A | |
| SCHEMBL20481915 | 0.82 | ABCB1 (0.39) | LARS1ALOX15HTR1A | |
| Hydrochloric Acid SCHEMBL23004824 | 0.81 | CXCR4 (0.43) | LARS1HTR1A | |
| SCHEMBL16256484 | 0.81 | LARS1 (0.47) | LARS1LMNAALOX15 | |
| SCHEMBL13035602 | 0.81 | LARS1 (0.60) | LARS1 | |
| SCHEMBL12831366 | 0.81 | LARS1 (0.60) | LARS1 | |
| SCHEMBL20481916 | 0.81 | LARS1 (0.42) | LARS1LMNAALOX15 | |
| SCHEMBL20481884 | 0.79 | LARS1 (0.41) | LARS1LMNAALOX15 | |
| SCHEMBL20481923 | 0.76 | LARS1 (0.43) | LARS1LMNAALOX15HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180244699-A1 | 1-HYDROXY-3H-2,1-BENZOXABOROLE DERIVATIVES AND THEIR USE AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244699-A1 | 1-HYDROXY-3H-2,1-BENZOXABOROLE DERIVATIVES AND THEIR USE AS MICROBIOCIDES | CBR3, HCRTR2, HCAR3 | LARS1 4143/4885LMNA 4316/4885ALOX15 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.